CCL22 and T-cell non-Hodgkin lymphoma: Since bexarotene significantly decreased expression of CCL22 mRNA in the tumor microenvironment, we hypothesized that bexarotene, as well as anti-CCL22 antibody (Ab) could suppress the growth of EL-4 T cell lymphoma in vivo.